Sagimet Biosciences Inc. announced positive 52-week data from an open-label Phase 3 clinical trial conducted by its license partner, Ascletis Pharma Inc., evaluating the long-term safety of ASC40 (denifanstat) tablets in patients with moderate to severe acne. The topline results from this trial were reported in a press release issued by Ascletis on January 29. Denifanstat is an oral fatty acid synthase (FASN) inhibitor developed by Ascletis for acne in China and by Sagimet for MASH in other regions. In June 2025, Ascletis also reported that denifanstat met all primary, key secondary, and secondary endpoints in a separate 480-patient randomized, double-blind, placebo-controlled Phase 3 trial for moderate to severe acne vulgaris. Results from both studies have already been presented.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sagimet Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9646826-en) on February 02, 2026, and is solely responsible for the information contained therein.